Table 1.
Baseline characteristics of study population
| All cohort (n = 312) | RTE high (n = 51) | RTE low (n = 261) | p | |
|---|---|---|---|---|
| Treatment arm | ||||
| SIRT (+ Sorafenib) | 138 (44.2%) | 17 (33.3%) | 121 (46.4%) | 0.086 |
| Sorafenib | 174 (55.8%) | 34 (66.7%) | 140 (53.6%) | |
| Gender (male) | 276 (88.4%) | 43 (84.3%) | 233 (89.2%) | 0.310 |
| Age (> 65 years) | 147 (47.1%) | 23 (45.1%) | 124 (47.5%) | 0.752 |
| ECOG-PS | ||||
| 0 | 217 (69.5%) | 32 (62.7%) | 185 (70.9%) | 0.201 |
| 1&2 | 92 (29.5%) | 19 (37.3%) | 73 (28.0%) | |
| Missing | 3 (0.9%) | – | 3 (1.1%) | |
| Liver cirrhosis (yes) | 250 (80.1%) | 43 (84.3%) | 207 (79.3%) | 0.412 |
| Hepatitis B | 33 (10.5%) | 7 (13.7%) | 26 (9.9%) | 0.424 |
| Hepatitis C | 73 (23.3%) | 15 (29.4%) | 58 (22.2%) | 0.267 |
| Alcoholic liver disease | 133 (42.6%) | 21 (41.1%) | 112 (42.9%) | 0.818 |
| Lesion diameter > 65 mm | 87 (27.8%) | 17 (33.3%) | 70 (26.8%) | 0.342 |
| Portal vein infiltration | 131 (42.0%) | 21 (41.2%) | 110 (42.1%) | 0.897 |
| Extrahepatic spread | 65 (20.8%) | 13 (25.4%) | 52 (19.9%) | 0.370 |
| Child–Pugh | ||||
| A | 289 (92.6%) | 47 (92.1%) | 242 (92.7%) | 0.776 |
| B | 23 (7.4%) | 4 (7.9%) | 19 (7.3%) | |
| BCLC | ||||
| A&B | 100 (32.1%) | 15 (29.4%) | 85 (32.6%) | 0.658 |
| C | 212 (67.9%) | 36 (70.6%) | 176 (67.4%) | |
| AFP ≥ 400 | 113 (36.2%) | 17 (33.3%) | 96 (36.7%) | 0.495 |
| ALBI grade | 0.282 | |||
| 1 | 153 (49.0%) | 22 (43.1%) | 131 (50.1%) | |
| 2 | 153 (49.0%) | 29 (56.9%) | 124 (47.5%) | |
| Missing | 6 (1.9%) | – | 6 (2.3%) |
AFP alfa-fetoprotein, ALBI albumin–bilirubin, BCLC Barcelona Clinic Liver Cancer, CI confidence interval, ECOG-PS Eastern Cooperative Oncology Group Performance Score, HR hazard ratio, PVI portal vein invasion